Copy Link Print Information

BCL9L Antibody (YA7105)

Customer Review

Based on 1 Customer Validation

BCL9L Antibody (YA7105) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BCL9L.

For research use only. We do not sell to patients.
  • Host:

    Mouse

  • Isotype:

    IgG1

  • Application:

    FC, ELISA

  • Reactivity :

    Human

  • Formulation:

    Supplied in PBS with 0.05% sodium azide

  • Conjugation:
    Non-conjugated
  • BCL9L Antibody (YA7105) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download
Related Products:
Top Publications Citing

Use of MCE Products

Applications

Application
FC Info
FC: Flow Cytometry
ELISA Info
ELISA: Enzyme Linked Immunosorbent Assay
Dilution Ratio 1:200-1:400 1:10000

Product Details

Description

BCL9L Antibody (YA7105) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BCL9L.

  • Host Mouse
  • Clonality Monoclonal
  • Species Reactivity
    Human
  • Calculated Molecular Weight Predicted band size: 157kDa;
Species Reactivity Database
Immunogen

Purified recombinant fragment of human BCL9L (AA: 606-751) expressed in E. Coli.

Sensitivity

Endogenous

Purification

affinity purified.

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG1

Product Properties

  • Appearance

    Liquid

  • Formulation

    Supplied in PBS with 0.05% sodium azide

  • Concentration

    Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Background

  • Function

    BCL9L transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1

  • Subcellular Localization

    Nucleus

  • Expression


    Tissue_Specificity: Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level). Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor

  • Isoforms & Post-Translational Modification

    Q86UU0 has four isomers: Q86UU0-1: 157129 Da (predicted); Q86UU0-2: 156529 Da (predicted); Q86UU0-3: 145906 Da (predicted); Q86UU0-4: 152547 Da (predicted).

  • Subunit

    Found in a complex with CDC73; CTNNB1 and PYGO1

  • SwissProt ID

    Q86UU0

BCL9L Antibody (YA7105) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • BCL9L Antibody (YA7105) Product Image
    1/16
  • BCL9L Antibody (YA7105) Product Image